Sign up to save your podcasts
Or
Share Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL
Dr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab.
They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.
View all episodes
By Rahul Banerjee, MD
4.8
2727 ratings
Dr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab.
They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.
More shows like The HemOnc Pulse
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
320 Listeners
JAMA Clinical Reviews
497 Listeners
Hematologic Oncology Update
75 Listeners
Research To Practice | Oncology Videos
121 Listeners
The Hematologist
28 Listeners
Core IM | Internal Medicine Podcast
1,146 Listeners
OncoPharm
187 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
369 Listeners
Blood Podcast
52 Listeners
Healthcare Unfiltered
138 Listeners
Blood Cancer Talks
48 Listeners
Two Onc Docs
192 Listeners
WolverHeme Happy Hour
31 Listeners